Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$3.19 USD
-0.10 (-3.04%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.20 +0.01 (0.31%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/11/2025
Time: -- |
9/2025 | $-0.33 | 0.00% |
Earnings Summary
For their last quarter, Perspective Therapeutics, Inc. (CATX) reported earnings of -$0.30 per share, in line with the Zacks Consensus Estimate. This reflects a breakeven earnings surprise. Look out for CATX's next earnings release expected on November 11, 2025. For the next earning release, we expect the company to report earnings of -$0.33 per share, reflecting a year-over-year decrease of 57.14%.
Earnings History
Price & Consensus
Zacks News for CATX
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
CATX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates
Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround
CATX FAQs
Based on past history, Zacks believes Perspective Therapeutics, Inc. (CATX) will report their next quarter earnings on November 11, 2025. For the next earning release, we expect the company to report earnings of -0.33 per share, reflecting a year-over-year increase of -57.14.
Based on past history, Zacks believes Perspective Therapeutics, Inc. (CATX) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 11, 2025.
The Zacks Consensus Estimate for Perspective Therapeutics, Inc. (CATX) for the quarter ending September 2025 is $-0.33 a share. We expect Perspective Therapeutics, Inc. (CATX) to report earnings in line with the consensus estimate of $-0.33 per share
In the earnings report for the quarter ending in June 2024, Perspective Therapeutics, Inc. (CATX) announced earnings of $-0.17 per share versus the Zacks Consensus Estimate of $-0.21 per share, representing a surprise of -19.05%.